Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05450406
Other study ID # Trainome-031
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 2022
Est. completion date July 2026

Study information

Verified date August 2022
Source Inland Norway University of Applied Sciences
Contact Knut Sindre Mølmen, PhD
Phone +47 61 28 85 53
Email knut.sindre.molmen@inn.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Healthy Life Centers (Norwegian, 'Frisklivssentralen') is a municipal service in Norway that aims to promote both physical and mental health, as well as to limit the development of non-communicable diseases. Previous research has shown that receiving follow-up from Healthy Life Centers has led to higher levels of daily physical activity, in addition to improved self-reported health and quality of life among the participants. However, there is a lack of studies that have examined what kind of physiological health effects can be expected from participating in the Healthy Life Center's follow-up. In this study, responses to the 12-week physical activity program of the Healthy Life Center will be compared with the responses in a negative control group that does not receive such follow-up. Both the intervention group and the reference group (the negative control group) will carry out the same tests and measurements before and after the 12 week period. The tests will include measurements of anthropometric variables (body height, body weight and waist circumference), body composition, arterial stiffness, resting blood pressure and blood variables (blood glucose, long-term blood glucose, blood lipid profile and inflammation markers), in addition to physical tests of mobility, balance, maximum aerobic capacity (maximal oxygen consumption) and maximum muscle strength. Questionnaires related to adherence to the Healthy Life Center follow-up, socio-demographic variables, eating and drinking habits, activity level, perceived physical fitness, motivation for exercise, and health-related quality of life will also be included.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date July 2026
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Intervention group Inclusion Criteria: - >18 years of age - Receiving follow-up from the Healthy Life Center Exclusion Criteria: - In average >1 weekly exercise training session the last three months Reference group Inclusion Criteria: - >18 years of age Exclusion Criteria: - In average >1 weekly exercise training session the last three months - Receiving follow-up from the Healthy Life Center

Study Design


Intervention

Other:
Physical activity
The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Inland Norway University of Applied Sciences

Outcome

Type Measure Description Time frame Safety issue
Other Activity level Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Other Adherence to the 12-week intervention (measured as the number of sessions the participant attended divided by the number of sessions prescribed) For the intervention group During the 12-week intervention
Other Compliance to the 12-week intervention (measured as the number of sessions the participant conducted the session as prescribed divided by the number of total sessions) For the intervention group During the 12-week intervention
Primary Maximal oxygen consumption (measured in mL/kg body mass/min) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Balance, measured using the "single leg stance test" (measured in seconds) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Mobility, measured using the "sit-and-reach" and the "back stretch" test (measured in centimeters) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Fat mass (measured in kilograms) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Lean mass (measured in kilograms) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Bone mineral density ( measured in g/cm2) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Visceral fat (measured in grams) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Blood glucose levels (serum, fasted state) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Cholesterol and total triglyceride levels (serum, fasted state) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Resting blood pressure Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Systemic inflammation markers (levels of c-reactive protein, TNF-alpha, interleukin 6 and interleukin 8 in serum, fasted state) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Arterial stiffness Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Health-related quality of life (measured using the SF-36 questionnaire; scores from 0-100, where a higher score means a better outcome) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Body mass index Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Maximal muscle strength (measured in newtons produced during a leg press exercise) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Maximal muscle power (measured in watts produced during a leg press exercise) Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
Secondary Waist circumference Difference in change between the two study arms from before to after the 12-week intervention/control period From before to after the 12-week intervention/control period
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2